Remember 2015, when pharma was shattering deal-volume records? These days, it seems like a pretty long time ago.
In Q3, deal activity has headed south–both in volume and in value–compared with the year-ago quarter, according to PwC’s Global Pharma & Life Sciences Deals Insights Q3 2016 Update. And the decrease in value has been “considerable.”
The reason? Pharma hasn’t seen as many large deals–especially those greater than $1 billion. The industry registered just 7 in the quarter, with Pfizer’s $14.1 billion Medivation buy taking the cake.
And the reasons for that? They include potential interest rate movements and recent attention on drug pricing, which has brought an unwelcome spotlight on more than a few specialty players. As a result, potential acquirers are waiting “to see how this trend develops in the next few quarters,” the authors wrote.
As PwC notes, the recent M&A decline means “deal volumes in the future have the ability to trend upward.” But that doesn’t mean they will.
Instead, what’s more likely is that they’ll stay “depressed” until “uncertainty around general economic factors and industry conditions” are cleared up.
And even if deal volumes head upward again by the end of the year–an event that’s possible, PwC acknowledged, considering that companies including Valeant and Endo are currently assessing their portfolios–2016’s total deal value may still look low relative to prior years.
Potential acquirers are becoming “more disciplined with deal pricing” and scouting smaller targets.
If that shift in thinking doesn’t sound familiar, consider Allergan: After last year agreeing to technically buy Pfizer in a record-breaking $160 billion megadeal–later thwarted by the U.S. Treasury–Allergan recently committed itself to vastly smaller “stepping-stone deals,” as CEO Brent Saunders likes to call them.
By Carly Helfand
Source: Fierce Pharma
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.
